Program
rulonilimab
Also written as “F520”, “F520 combined with chemotherapy” and “Rulonilimab”.
Its studies are mostly in Neoplasms, Unknown Primary · Uterine Cervical Neoplasms · Carcinoma, Hepatocellular · Carcinoma, Non-Small-Cell Lung · Lymphoma, T-Cell, Peripheral, led by Lunan Pharmaceutical Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Lunan Pharmaceutical Group | 93 open or running | phase 3since Jun 2, 2022 | Jul 1, 2020 | Dec 30, 2027phase 3 · NCT07761429 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 1, 2020First studies: 2 phase 2 studiesFirst studyNCT04457869, NCT04457830
- Nov 18, 2020Phase 2 study in Locally Advanced or Metastatic Urothelial Cell CarcinomaNCT04636515 · 80 enrolled
- Dec 17, 2021Phase 2 study in Parkinson Disease 4, Autosomal Dominant Lewy BodyNCT05178836 · 62 enrolled
- Jun 2, 2022Phase 3 study in Carcinoma, HepatocellularNCT05408221 · 576 planned · China
- Feb 3, 20232 phase 2 studiesNCT05740215, NCT05741021
- Dec 24, 2024Phase 3 study in Uterine Cervical NeoplasmsNCT06755515 · 510 planned · China
- May 27, 2026Phase 3 study in Neoplasms, Unknown PrimaryNCT07761429 · 402 planned · China
Ahead
- Dec 30, 2027Primary completion: phase 3 study in Neoplasms, Unknown PrimaryNCT07761429
- Sep 2028Primary completion: phase 3 study in Uterine Cervical NeoplasmsNCT06755515
TargetBeta
“A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), ”NCIt, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
| sasanlimab | Pfizer | phase 3 | 4 |
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07761429Neoplasms, Unknown Primary · China | 3 | Recruiting | Dec 30, 2027 | 402 |
| NCT06755515Uterine Cervical Neoplasms · China | 3 | By invitation | Sep 2028 | 510 |
| NCT05741021Carcinoma, Non-Small-Cell Lung · China | 2 | UNKNOWN | Oct 25, 2024 | 84 |
| NCT05740215Solid Tumors · China | 2 | UNKNOWN | May 22, 2024 | 158 |
| NCT05408221Carcinoma, Hepatocellular · China | 3 | Recruiting | Aug 1, 2025 | 576 |
| NCT05178836Parkinson Disease 4, Autosomal Dominant Lewy Body | 2 | UNKNOWN | Dec 31, 2023 | 62 |
| NCT04636515Locally Advanced or Metastatic Urothelial Cell Carcinoma | 2 | UNKNOWN | Mar 2022 | 80 |
| NCT04457869Primary Central Nervous System Lymphoma | 2 | UNKNOWN | Jul 31, 2022 | 43 |
| NCT04457830Lymphoma, T-Cell, Peripheral | 2 | UNKNOWN | Jul 31, 2022 | 105 |
How it is read
Names in the registry
- “F520”, 5 entries
- “F520 combined with chemotherapy”, 1 entry
- “Rulonilimab”, 1 entry
- “Rulonilimab+Lenvatinib”, 1 entry
- “F520+F007”, 1 entry
Conditions, from the studies’ own filings
- Neoplasms, Unknown Primary, 1 study
- Uterine Cervical Neoplasms, 1 study
- Carcinoma, Hepatocellular, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
- Lymphoma, T-Cell, Peripheral, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.